In September 2020, we hosted our International Research Workshop virtually, and in conjunction with our Together We Will Virtual Weekend. Over 190 physicians and researchers signed up for the 2020 Research Workshop, expanding our worldwide participation to 72 institutions from 31 countries.
Agenda
Welcome
Jeanne Whiting
President and Co-Founder, DTRF
Mouse models in desmoid tumors.
Benjamin Alman, MD
Professor & Chair, Orthopedic Surgery, Duke University
The Desmoid Tumor Dependency Map.
Jesse Boehm, PhD
Scientific Director of the Cancer Dependency Map, Associate Director of the Cancer Program, Director of the Broad Cancer Model Development Center, The Broad Institute of MIT and Harvard
Identifying and characterizing dependency factors in a genetic Xenopus tropicalis desmoid tumor model.
Kris Vleminckx, PhD
Professor of Developmental Biology, Ghent University
Stable isotope resolved metabolomics to interrogate the interactions between stroma and desmoid tumors.
Kelly Mercier, PhD
Adjunct Associate, Duke University; Medical Science Liaison, Jazz Pharmaceuticals, Inc.
Genome-wide DNA methylation profiling of desmoid tumors.
Joanna Przybyl, PhD
Instructor, Department of Pathology, Stanford University
Jun and its Connections with Wnt and Notch.
Gerlinde Wernig, MD
Assistant Professor, Department of Pathology, and Tristan Lerbs, PhD, Post doctoral Researcher, Stanford University School of Medicine
The mechanism of Sorafenib in desmoid-type fibromatosis.
Anne-Rose W Schut, MD, PhD candidate
Surgical Oncology, Erasmus Medical Center Cancer Institute
Activity of taxanes in progressive or symptomatic desmoid tumors.
Javier Martin Broto, MD, PhD
Instituto de Biomedicina de Sevilla (IBIS)
Association of CTNNB1 mutation subtypes with responses to systemic therapy in patients with desmoid tumors.
Breelyn A. Wilky, MD
Associate Professor, University of Colorado Anschutz Medical Campus
Christina Kosyla
Desmoid tumor patient and advocate
Desmoid fibromatosis management in tertiary care center in India- Lessons learned.
Sameer Rastogi, MD
Medical Oncologist, All India Institute of Medical Sciences
The DTRF Virtual Tumor Board.
Aaron Weiss, DO
Associate Professor of Pediatrics, Maine Medical Center (Chair, DTRF Medical Advisory Board)
The DTRF Natural History Study- Sept 2020 Update.
Kelly Mercier, PhD
Principal Investigator, DTRF Patient Registry
AL102, Oral Gamma-Secretase Inhibitor for the Treatment of Patients Living with Desmoid Tumors.
Chen Duksin, MD, MBA
Executive Medical Director, Ayala Pharmaceuticals
ARST1921: A Safety Pharmacokinetic and Efficacy Study of a y-Secretase Inhibitor, Nirogacestat (PF-03084014), in Children with Adolescents with Progressive, Unresectable Desmoid Tumors.
Fariba Navid, MD
Associate Professor at the Keck School of Medicine and Medical Director of Clinical Research Support Office for the Cancer and Blood Disease Institute at Children’s Hospital Los Angeles